Literature DB >> 19937477

Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?

Ioannis T Konstantinidis1, Vikram Deshpande, Hui Zheng, Jennifer A Wargo, Carlos Fernandez-del Castillo, Sarah P Thayer, Vasiliki Androutsopoulos, Gregory Y Lauwers, Andrew L Warshaw, Cristina R Ferrone.   

Abstract

BACKGROUND: Lymph node metastases are prognostically significant in pancreatic ductal adenocarcinoma. Little is known about the significance of direct lymph node invasion. AIM: The aim of this study is to find out whether direct lymph node invasion has the same prognostic significance as regional nodal metastases.
METHODS: Retrospective review of patients resected between 1/1/1993 and 7/31/2008. "Direct" was defined as tumor extension into adjacent nodes, and "regional" was defined as metastases to peripancreatic nodes.
RESULTS: Overall, 517 patients underwent pancreatic resection for adenocarcinoma, of whom 89 had one positive node (direct 26, regional 63), and 79 had two positive nodes (direct 6, regional 68, both 5). Overall, survival of node-negative patients was improved compared to patients with positive nodes (N0 30.8 months vs. N1 16.4 months; p < 0.001). There was no survival difference for patients with direct vs. regional lymph node invasion (p = 0.67). Patients with one positive node had a better overall survival compared to patients with >/=2 positive nodes (22.3 and 15 months, respectively; p < 0.001). The lymph node ratio (+LN/total LN) was prognostically significant after Cox regression (p < 0.001).
CONCLUSIONS: Isolated direct invasion occurs in 20% of patients with one to two positive nodes. Node involvement by metastasis or by direct invasion are equally significant predictors of reduced survival. Both the number of positive nodes and the lymph node ratio are significant prognostic factors.

Entities:  

Mesh:

Year:  2009        PMID: 19937477      PMCID: PMC3135335          DOI: 10.1007/s11605-009-1096-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  20 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy.

Authors:  O Ishikawa; H Ohigashi; Y Sasaki; T Kabuto; H Furukawa; S Nakamori; S Imaoka; T Iwanaga; T Kasugai
Journal:  Surgery       Date:  1997-03       Impact factor: 3.982

3.  Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database.

Authors:  Roderich E Schwarz; David D Smith
Journal:  Ann Surg Oncol       Date:  2006-09-06       Impact factor: 5.344

4.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

5.  Prognostic significance of lymph node metastases and ratio in esophageal cancer.

Authors:  Matthew Wilson; Ernest L Rosato; Karen A Chojnacki; Inna Chervoneva; John C Kairys; Herbert E Cohn; Francis E Rosato; Adam C Berger
Journal:  J Surg Res       Date:  2007-08-28       Impact factor: 2.192

6.  Pancreatic adenocarcinoma: the actual 5-year survivors.

Authors:  Cristina R Ferrone; Murray F Brennan; Mithat Gonen; Daniel G Coit; Yuman Fong; Sun Chung; Laura Tang; David Klimstra; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2007-11-20       Impact factor: 3.452

7.  Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer.

Authors:  Timothy M Pawlik; Ana L Gleisner; John L Cameron; Jordan M Winter; Lia Assumpcao; Keith D Lillemoe; Christopher Wolfgang; Ralph H Hruban; Richard D Schulick; Charles J Yeo; Michael A Choti
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

8.  Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer.

Authors:  Michael G House; Mithat Gönen; William R Jarnagin; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Murray F Brennan; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2007-09-04       Impact factor: 3.452

9.  Accuracy of staging node-negative pancreas cancer: a potential quality measure.

Authors:  James S Tomlinson; Sushma Jain; David J Bentrem; Evangelos G Sekeris; Melinda A Maggard; O Joe Hines; Howard A Reber; Clifford Y Ko
Journal:  Arch Surg       Date:  2007-08

10.  Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

Authors:  Thomas Schnelldorfer; Adam L Ware; Michael G Sarr; Thomas C Smyrk; Lizhi Zhang; Rui Qin; Rachel E Gullerud; John H Donohue; David M Nagorney; Michael B Farnell
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

View more
  15 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?

Authors:  Linda M Pak; Mithat Gonen; Kenneth Seier; Vinod P Balachandran; Michael I D'Angelica; William R Jarnagin; T Peter Kingham; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  Abdom Radiol (NY)       Date:  2018-08

3.  Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.

Authors:  Toshihiko Masui; Ryuichiro Doi; Yoshiya Kawaguchi; Asahi Sato; Kenzo Nakano; Tatsuo Ito; Takayuki Anazawa; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2016-02-09       Impact factor: 2.549

4.  A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.

Authors:  Russell Lewis; Jeffrey A Drebin; Mark P Callery; Douglas Fraker; Tara S Kent; Jenna Gates; Charles M Vollmer
Journal:  HPB (Oxford)       Date:  2012-09-24       Impact factor: 3.647

Review 5.  Ductal adenocarcinoma of the pancreatic head: a focus on current diagnostic and surgical concepts.

Authors:  Mehdi Ouaïssi; Urs Giger; Guillaume Louis; Igor Sielezneff; Olivier Farges; Bernard Sastre
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

6.  Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study.

Authors:  Hyung Sun Kim; Tae Ho Hong; Young-Kyoung You; Joon Seong Park; Dong Sup Yoon
Journal:  Surg Today       Date:  2021-04-08       Impact factor: 2.549

Review 7.  Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy: A Meta-Analysis.

Authors:  Eric Jinyi Wu; Tousif Kabir; Joseph J Zhao; Brian K P Goh
Journal:  World J Surg       Date:  2021-10-05       Impact factor: 3.352

8.  Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes.

Authors:  Pavan Tummala; Todd Howard; Banke Agarwal
Journal:  Clin Transl Gastroenterol       Date:  2013-03-21       Impact factor: 4.488

9.  Current state of surgical management of pancreatic cancer.

Authors:  Thilo Hackert; Markus W Büchler; Jens Werner
Journal:  Cancers (Basel)       Date:  2011-03-10       Impact factor: 6.639

10.  Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer.

Authors:  Sung Hyun Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.